跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NG-12
首页
药物
NG-12
NG-12
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Controlled release oxycodone compositions
US 2006057210 A1
申请人: PURDUE PHARMA COMPANY
优先权: 2001
US
10 件公开
US 2007275062 A1
申请人: OSHLACK BENJAMIN
优先权: 2007
US
3 件公开
US 2008075781 A1
申请人: PURDUE PHARMA COMPANY
优先权: 2007
US
3 件公开
US 2007275065 A1
申请人: PURDUE PHARMA COMPANY
优先权: 2007
US
Treating allergic and inflammatory conditions
US 7405223 B2
申请人: SCHERING CORP
优先权: 2001
US
4 件公开
METHOD AND PHARMACEUTICAL COMPOSITION FOR OBTAINING THE PLASMATIC PROGESTERONE LEVELS REQUIRED FOR DIFFERENT THERAPEUTIC INDICATIONS
US 2011104289 A1
申请人: POSI VISIONARY SOLUTIONS LLP
优先权: 2008
CN
US
2 件公开
Method of isolation of culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same
US 12447181 B2
申请人: KARIS BIO INC
优先权: 2019
CN
US
2 件公开
Galenical form for oral administration with prolonged release of molsidomine
US 7767227 B2
申请人: THERABEL PHARMACEUTICALS LTD
优先权: 2000
US
2 件公开
Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
US 7070803 B2
申请人: NYCOMED AUSTRIA GMBH
优先权: 2001
US
2 件公开
Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US 8697702 B2
申请人: WANG YANFENG
优先权: 2009
US
2 件公开
USE OF URODILATIN FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF CARDIOVASCULAR, RENAL, PULMONARY AND NEURONAL SYNDROMES WHILE AVOIDING A REBOUND
US 2013197188 A1
申请人: FORSSMANN WOLF-GEORG
优先权: 2010
US
2 件公开
Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs
US 8802143 B2
申请人: SHANE GUANG-TZUU
优先权: 2011
US
2 件公开
Application of nitro fatty acid in preparation of product for predicting, preventing and improving adverse cardiovascular events of acute coronary syndrome patients
CN 118045076 A
申请人: BEIJING INST OF HEART LUNG AND BLOOD VESSEL DISEASES
优先权: 2024
CN
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈